{"entity":{"id":"ddr-inhibitor-payloads","kind":"term","name":"DNA damage response inhibitor payloads","aka":["DDR inhibitor payloads","repair-checkpoint inhibitor payloads"],"tldr":"These payloads block the systems cells use to cope with damaged DNA. One strategy puts a damage-causing drug and a repair-checkpoint inhibitor on the same antibody.","summary":"DNA damage response inhibition is a payload mechanism only when the inhibitor is carried by the conjugate. CLIO-8221 combines exatecan with the ATR inhibitor berzosertib on a HER2-directed antibody. Its published trial-design abstract describes preclinical rationale and a phase 1/2 study, not clinical proof that the combination overcomes resistance. Giving a separate PARP, ATR or WEE1 inhibitor alongside an antibody-drug conjugate is a combination regimen, not evidence of that inhibitor being an attached payload.","asOf":"2026-11-08","links":[{"label":"CLIO-8221 phase 1/2 trial-design abstract (2026)","url":"https://doi.org/10.1200/JCO.2026.44.16_suppl.TPS3162"},{"label":"Azenosertib plus conjugates: a separate-drug combination study (2026)","url":"https://doi.org/10.1016/j.isci.2026.116390"}],"tags":[],"related":["atr-inhibitor-payloads"],"cancers":[],"sections":[],"technologies":["adc","dual-payload-adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["payload"],"trials":["nct07300943"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["PARP and WEE1 combination studies retrieved in this review were not relabelled as payload studies. Each proposed repair-inhibitor payload needs a source identifying what is physically carried."],"category":"ADC chemistry"},"route":"/terms/ddr-inhibitor-payloads/","neighbours":{"term":[{"id":"atr-inhibitor-payloads","kind":"term","name":"ATR inhibitor payloads","route":"/terms/atr-inhibitor-payloads/"},{"id":"next-generation-adc-payloads","kind":"term","name":"Next-generation antibody-conjugate payloads","route":"/terms/next-generation-adc-payloads/"},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"dual-payload-adc","kind":"technology","name":"Dual-payload ADC","route":"/technologies/dual-payload-adc/"}],"trial":[{"id":"nct07300943","kind":"trial","name":"Study in Advanced Solid Tumor Patients","route":"/trials/nct07300943/"}]}}